Published in Biol Blood Marrow Transplant on February 28, 2012
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics (2005) 6.45
New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens (2003) 3.30
Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am (1999) 2.86
Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 2.29
Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood (2007) 1.58
Modelling competing risks in cancer studies. Stat Med (2006) 1.52
Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood (1989) 1.46
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood (2002) 1.19
Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood (1997) 1.03
Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol (1986) 0.98
Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia. Exp Hematol (2007) 0.96
Risk factors affecting outcome of second HLA-matched sibling donor transplantations for graft failure in severe acquired aplastic anemia. Biol Blood Marrow Transplant (2009) 0.93
An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood (1994) 0.89
Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Biol Blood Marrow Transplant (2010) 0.89
HLA-DRB1*15 and pediatric aplastic anemia. Haematologica (2002) 0.89
Association of human leukocyte antigen-DRB1 alleles with disease susceptibility and severity of aplastic anemia in Korean patients. Hum Immunol (2008) 0.86
Aplastic anemia is associated with HLA-DRB1*1501 in northern Han Chinese. Int J Hematol (2000) 0.85
HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol (1992) 0.83
HLA-DR15, reduced relapse rate and improved survival after HLA identical sibling hemopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 0.82
Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy. J Pak Med Assoc (2004) 0.81
HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood (1995) 0.81
HLA DR15 and immunobiologic outcomes. Biol Blood Marrow Transplant (2007) 0.81
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell (2009) 11.36
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood (2007) 9.82
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth (2009) 8.28
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 7.10
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
The carbon balance of terrestrial ecosystems in China. Nature (2009) 6.84
Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys (2006) 6.51
Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest (2005) 5.91
Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell (2009) 5.49
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Aging, progenitor cell exhaustion, and atherosclerosis. Circulation (2003) 5.19
Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg (2009) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab (2007) 4.16
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med (2007) 3.61
Mobile interspersed repeats are major structural variants in the human genome. Cell (2010) 3.60
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med (2012) 3.39
Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet (2012) 3.34
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood (2007) 3.15
Modeling quantitative trait Loci and interpretation of models. Genetics (2005) 3.15
One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med (2014) 3.07
Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns. Nat Immunol (2008) 3.05
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2007) 3.03
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol (2010) 2.99
Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence (2013) 2.98
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood (2009) 2.87
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Fiber formation across the bacterial outer membrane by the chaperone/usher pathway. Cell (2008) 2.69
Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int (2003) 2.69
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med (2014) 2.69
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol (2007) 2.66
Cell wall stress responses in Bacillus subtilis: the regulatory network of the bacitracin stimulon. Mol Microbiol (2003) 2.62
Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell (2012) 2.60
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Global analysis of the Bacillus subtilis Fur regulon and the iron starvation stimulon. Mol Microbiol (2002) 2.55
A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol (2012) 2.54
Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med (2006) 2.51
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet (2012) 2.47
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis (2004) 2.47
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood (2008) 2.34
Antibiotics that inhibit cell wall biosynthesis induce expression of the Bacillus subtilis sigma(W) and sigma(M) regulons. Mol Microbiol (2002) 2.32
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol (2010) 2.31
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood (2002) 2.24
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood (2005) 2.23
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
Ascaris suum draft genome. Nature (2011) 2.16
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
Evaluation of terrestrial carbon cycle models for their response to climate variability and to CO2 trends. Glob Chang Biol (2013) 2.13
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Immune-related microRNAs are abundant in breast milk exosomes. Int J Biol Sci (2011) 2.11
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med (2011) 2.08
The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med (2009) 2.07
Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc (2003) 2.07
Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer (2003) 2.06
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Exploring the engine of anthropogenic iron cycles. Proc Natl Acad Sci U S A (2006) 2.03
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood (2011) 2.03